[Federal Register Volume 79, Number 6 (Thursday, January 9, 2014)]
[Notices]
[Pages 1646-1647]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-00126]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: The Development of a 
Veterinary Rabies Vaccine Based on the ERAg3m Virus Strain

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an exclusive license 
to practice the inventions embodied in U.S. Provisional Patent 
Application No. 60/727,038, entitled ``Method of Sequencing Whole Viral 
Genomes, Related Compositions, and Genome Sequences'', filed October 
14, 2005 (HHS Ref. No. E-326-2013/0-

[[Page 1647]]

US-01); PCT Patent Application No. PCT/US2006/040134, entitled ``Rabies 
Virus Compositions and Methods'', filed October 13, 2006, (E-326-2013/
0-PCT-02); and Chinese Patent Application No. 200680038314.4, entitled 
``Rabies Virus Compositions and Methods'', filed October 13, 2006 (HHS 
Ref. No. E-326-2013/0-CN-06). The patent rights in these inventions 
have been assigned to the Government of the United States of America. 
The prospective exclusive license territory is China, and the field of 
use may be limited to ``Rabies vaccines based on the ERAg3m virus 
strain for veterinary use only.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 10, 2014 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Whitney Blair, J.D., M.P.H., Licensing and Patenting 
Manager, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-4937; Facsimile: (301) 402-0220; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: This license specifically concerns a highly 
attenuated rabies virus, ERAg3m, with a mutation in the glycoprotein 
(G) gene and a switch of the G gene with the matrix protein gene in the 
viral genome. After a one-dose intramuscular vaccination, the ERAg3m 
virus protected 100% of mice and hamsters from lethal challenge. ERAg3m 
also may offer better protection than traditional inactivated 
vaccinations, as demonstrated in co-infection studies. This technology 
is capable of being developed into a one-dose rabies vaccine for human 
or veterinary use.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of the published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-00126 Filed 1-8-14; 8:45 am]
BILLING CODE 4140-01-P